DX-9065a Daiichi.
DX-9065a is a Factor Xa inhibitor under development by Daiichi as an anticoagulant for the potential treatment of cardiovascular indications, including thrombosis and angina. By March 1996, DX-9065a had entered phase I trials in Japan and Europe, and by November 1998, it was in phase II trials in Japan. In February 2003, phase II trials for the prevention of myocardial infarction in patients with unstable angina pectoris were ongoing in Japan, Europe and the US.
Kaiser
Brigitte
B
Friedrich Schiller University Jena, Center for Vascular Biology and Medicine, Nordhäuser Str 78, D-99089 Erfurt, Germany. kaiser@zmkh.ef.uni-jena.de
D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy*; D000925:Anticoagulants / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D065427:Factor Xa Inhibitors; D006801:Humans; D015394:Molecular Structure; D009281:Naphthalenes / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D011422:Propionates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*
C086910:(2S)-2-(4-(((3S)-1-acetimidoyl-3-pyrrolidinyl)oxy)phenyl)-3-(7-amidino-2-naphtyl)propanoic acid; D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009281:Naphthalenes; D011422:Propionates